이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Exelixis 관리

관리 기준 확인 3/4

Exelixis' CEO는 Mike Morrissey, Jul2010 에 임명되었습니다 의 임기는 13.92 년입니다. 총 연간 보상은 $ 16.42M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 34.24M 가치에 해당하는 회사 주식의 0.55% 직접 소유합니다. 34.24M. 경영진과 이사회의 평균 재임 기간은 각각 8.8 년과 7 년입니다.

주요 정보

Mike Morrissey

최고 경영자

US$16.4m

총 보상

CEO 급여 비율	7.3%
CEO 임기	13.9yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	8.8yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Recent updates

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs

Jul 07

CEO 보상 분석

Mike Morrissey 의 보수는 Exelixis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	n/a	n/a	US$208m
Sep 30 2023	n/a	n/a	US$92m
Jun 30 2023	n/a	n/a	US$164m
Mar 31 2023	n/a	n/a	US$154m
Dec 31 2022	US$17m	US$1m	US$182m
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m

보상 대 시장: Mike 의 총 보상 ($USD 16.42M )은 US 시장( $USD 8.45M ).

보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mike Morrissey (63 yo)

13.9yrs

테뉴어

US$16,423,307

보상

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.5yrs	US$519.97k	0.43% $ 27.9m
Michael Morrissey	CEO, President & Director	13.9yrs	US$16.42m	0.55% $ 35.7m
Christopher Senner	Executive VP & CFO	8.9yrs	US$4.95m	0.16% $ 10.1m
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	1.5yrs	US$5.65m	0.082% $ 5.3m
Jeffrey Hessekiel	Executive VP	10.3yrs	US$4.56m	0.12% $ 7.7m
Amy Peterson	Executive VP	less than a year	US$7.38m	데이터 없음
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	7.5yrs	데이터 없음	데이터 없음
Laura Dillard	Executive Vice President of Human Resources	9.6yrs	데이터 없음	데이터 없음
Anne Champsaur	Senior Vice President of Drug Safety	9.2yrs	데이터 없음	데이터 없음
William Berg	Senior Vice President of Medical Affairs	8.8yrs	데이터 없음	데이터 없음
Patrick Haley	Executive Vice President of Commercial	7.5yrs	US$4.65m	0.051% $ 3.4m
Stefan Krauss	VP & Head of Business Development	no data	데이터 없음	데이터 없음

8.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: EXEL 의 관리팀은 노련하고 경험 (평균 재직 기간 8.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.5yrs	US$519.97k	0.43% $ 27.9m
Michael Morrissey	CEO, President & Director	13.9yrs	US$16.42m	0.55% $ 35.7m
Jack Wyszomierski	Independent Director	20.3yrs	US$490.97k	0.11% $ 7.4m
George Poste	Independent Director	19.8yrs	US$482.22k	0.066% $ 4.3m
Charles Sawyers	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ronald Evans	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sue Eckhardt	Independent Director	less than a year	데이터 없음	0% $ 0
Mary Beckerle	Independent Director	less than a year	데이터 없음	0% $ 0
Julie Smith	Independent Director	7.8yrs	US$490.92k	0.0019% $ 122.4k
Maria Freire	Independent Director	6.2yrs	US$488.72k	0.021% $ 1.3m
Robert Oliver	Independent Director	1.1yrs	US$717.44k	0.0016% $ 102.1k
Tomas Heyman	Independent Director	1.1yrs	US$716.19k	0.0016% $ 102.1k

7.0yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: EXEL 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Exelixis 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis, Inc., Annual General Meeting, May 30, 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

Recent updates

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Consensus EPS estimates fall by 15%

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

CEO, President & Director exercised options and sold US$816k worth of stock

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Insider exercised options and sold US$234k worth of stock

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Independent Director notifies of intention to sell stock

Insufficient new directors